CN111050765B - 螺环化合物及其制造和使用方法 - Google Patents

螺环化合物及其制造和使用方法 Download PDF

Info

Publication number
CN111050765B
CN111050765B CN201880056725.9A CN201880056725A CN111050765B CN 111050765 B CN111050765 B CN 111050765B CN 201880056725 A CN201880056725 A CN 201880056725A CN 111050765 B CN111050765 B CN 111050765B
Authority
CN
China
Prior art keywords
formula
pharmaceutically acceptable
tautomer
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880056725.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111050765A (zh
Inventor
谢丽尔·A·格莱斯
O·D·韦伯
丹尼尔·J·布扎德
迈克尔·B·沙格哈飞
托德·K·琼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN111050765A publication Critical patent/CN111050765A/zh
Application granted granted Critical
Publication of CN111050765B publication Critical patent/CN111050765B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
CN201880056725.9A 2017-08-29 2018-08-28 螺环化合物及其制造和使用方法 Active CN111050765B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762551721P 2017-08-29 2017-08-29
US62/551,721 2017-08-29
PCT/US2018/048372 WO2019046318A1 (en) 2017-08-29 2018-08-28 SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Publications (2)

Publication Number Publication Date
CN111050765A CN111050765A (zh) 2020-04-21
CN111050765B true CN111050765B (zh) 2024-01-02

Family

ID=65527860

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880056725.9A Active CN111050765B (zh) 2017-08-29 2018-08-28 螺环化合物及其制造和使用方法

Country Status (27)

Country Link
US (1) US11142526B2 (enExample)
EP (1) EP3675847B1 (enExample)
JP (1) JP7257387B2 (enExample)
KR (1) KR20200046061A (enExample)
CN (1) CN111050765B (enExample)
AU (1) AU2018323459A1 (enExample)
BR (1) BR112020004101A2 (enExample)
CA (1) CA3072923A1 (enExample)
CL (1) CL2020000462A1 (enExample)
CO (1) CO2020001724A2 (enExample)
CR (1) CR20200089A (enExample)
DO (1) DOP2020000039A (enExample)
EA (1) EA202090312A1 (enExample)
EC (1) ECSP20013337A (enExample)
ES (1) ES2952332T3 (enExample)
GE (1) GEP20217327B (enExample)
IL (1) IL272580B (enExample)
JO (1) JOP20200023A1 (enExample)
MA (1) MA50041A (enExample)
MX (1) MX2020002251A (enExample)
NI (1) NI202000014A (enExample)
PE (1) PE20200664A1 (enExample)
PH (1) PH12020500372A1 (enExample)
SG (1) SG11202001022TA (enExample)
UA (1) UA126685C2 (enExample)
WO (1) WO2019046318A1 (enExample)
ZA (1) ZA202001208B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
CN109496213B (zh) 2016-05-12 2022-03-04 H.隆德贝克有限公司 螺环化合物及其制备和使用方法
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
BR112020003946A2 (pt) 2017-08-29 2020-09-08 Lundbeck La Jolla Research Center, Inc. compostos de espirociclo e métodos para produzir e usar os mesmos
ES2952332T3 (es) 2017-08-29 2023-10-30 H Lundbeck As Compuestos espirocíclicos y sus métodos de preparación y uso
KR20220034104A (ko) * 2019-07-09 2022-03-17 에프. 호프만-라 로슈 아게 신규 헤테로고리 화합물
JP7785755B2 (ja) * 2020-08-26 2025-12-15 エフ． ホフマン－ラ ロシュ アーゲー Ｍａｇｌ阻害剤として有用な複素環化合物
US11434222B2 (en) * 2020-11-13 2022-09-06 H. Lundbeck A/S MAGL inhibitors
US20250084065A1 (en) 2021-12-29 2025-03-13 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
CN119137114A (zh) 2022-05-04 2024-12-13 H.隆德贝克有限公司 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068797A (zh) * 2010-06-04 2013-04-24 赛诺菲 氨基甲酸六氟异丙基酯衍生物，其制备及其治疗用途
CN104159581A (zh) * 2012-01-06 2014-11-19 阿比德治疗公司 氨基甲酸酯化合物及其制备和使用方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070523A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
EP2065369A4 (en) 2006-08-23 2011-12-28 Astellas Pharma Inc UREA CONNECTION OR SALT THEREOF
AU2009221860A1 (en) 2008-03-05 2009-09-11 Targacept, Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CA2775703C (en) 2009-09-29 2014-07-08 Polyone Corporation Polyester articles having simulated metallic or pearlescent appearance
HUE043962T2 (hu) 2009-10-23 2019-09-30 Janssen Pharmaceutica Nv Diszubsztituált oktahidro-pirrolo[3,4-C]pirrolok mint orexin receptor modulátorok
CA2791672A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
HRP20191937T1 (hr) 2012-09-25 2020-01-10 F. Hoffmann - La Roche Ag Derivati heksahidropirolo [3,4-c]pirola i srodni spojevi kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za liječenje npr. bubrežnih bolesti
US9828379B2 (en) 2013-07-03 2017-11-28 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
US10093630B2 (en) * 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016149401A2 (en) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
WO2017021805A1 (en) 2015-07-31 2017-02-09 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
TWI738753B (zh) 2016-03-31 2021-09-11 日商武田藥品工業股份有限公司 雜環化合物
CN109496213B (zh) 2016-05-12 2022-03-04 H.隆德贝克有限公司 螺环化合物及其制备和使用方法
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190108B1 (ar) 2016-11-16 2023-09-17 H Lundbeck As تركيبات صيدلانية
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
HUE064559T2 (hu) 2016-11-16 2024-03-28 H Lundbeck As MAGL inhibitor kristályos formája
ES2952332T3 (es) 2017-08-29 2023-10-30 H Lundbeck As Compuestos espirocíclicos y sus métodos de preparación y uso
BR112020003946A2 (pt) 2017-08-29 2020-09-08 Lundbeck La Jolla Research Center, Inc. compostos de espirociclo e métodos para produzir e usar os mesmos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068797A (zh) * 2010-06-04 2013-04-24 赛诺菲 氨基甲酸六氟异丙基酯衍生物，其制备及其治疗用途
CN104159581A (zh) * 2012-01-06 2014-11-19 阿比德治疗公司 氨基甲酸酯化合物及其制备和使用方法
US9487495B2 (en) * 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis and Preclinical Evaluation of Sulfonamido-based [(11)C-Carbonyl]-Carbamates and Ureas for Imaging Monoacylglycerol Lipase;Lu Wang et al.;《Theranostics》;20160521;第6卷(第8期);第1147页左栏第1-2段、补充材料第37页 *

Also Published As

Publication number Publication date
CN111050765A (zh) 2020-04-21
ES2952332T3 (es) 2023-10-30
JOP20200023A1 (ar) 2020-02-02
US20200255427A1 (en) 2020-08-13
IL272580A (en) 2020-03-31
KR20200046061A (ko) 2020-05-06
MX2020002251A (es) 2020-07-20
NI202000014A (es) 2020-07-28
IL272580B (en) 2022-09-01
EP3675847B1 (en) 2023-07-12
ZA202001208B (en) 2021-08-25
EA202090312A1 (ru) 2020-08-05
GEP20217327B (en) 2021-12-10
JP7257387B2 (ja) 2023-04-13
BR112020004101A2 (pt) 2020-09-24
UA126685C2 (uk) 2023-01-11
RU2020107163A3 (enExample) 2022-03-15
JP2020532545A (ja) 2020-11-12
AU2018323459A1 (en) 2020-02-20
MA50041A (fr) 2020-07-08
SG11202001022TA (en) 2020-03-30
EP3675847C0 (en) 2023-07-12
CL2020000462A1 (es) 2020-07-10
CO2020001724A2 (es) 2020-02-28
PH12020500372A1 (en) 2020-12-07
RU2020107163A (ru) 2021-09-30
US11142526B2 (en) 2021-10-12
WO2019046318A1 (en) 2019-03-07
EP3675847A4 (en) 2021-01-06
PE20200664A1 (es) 2020-06-11
DOP2020000039A (es) 2020-08-31
ECSP20013337A (es) 2020-04-22
CA3072923A1 (en) 2019-03-07
CR20200089A (es) 2020-04-08
EP3675847A1 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
CN111050765B (zh) 螺环化合物及其制造和使用方法
CN116589466B (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
CN105732636B (zh) 杂芳化合物及其在药物中的应用
CN103797011B (zh) 作为c-Kit激酶抑制剂的化合物和组合物
CN111032034B (zh) 螺环化合物及其制造和使用方法
CN108601769B (zh) 吡唑化合物及其制备和使用方法
US11345681B1 (en) Inhibitors of fibroblast growth factor receptor kinases
CN109996790B (zh) 哌嗪氨基甲酸酯及其制备和使用方法
CN115448923A (zh) 嘧啶并环化合物及其制备方法和应用
CN105566321B (zh) 杂芳化合物及其在药物中的应用
BR112016012262A2 (pt) Pirrolo[2,3-d]pirimidinila, pirrolo[2,3-b]pirazinila e pirrolo[2,3-d]piridinil acrilamidas
AU2017382360A1 (en) Compounds, compositions and methods of use
CN105517547A (zh) 吡咯并吡咯氨基甲酸酯和相关的有机化合物、药物组合物及其医学用途
CN115335376A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶（btk）及其使用方法
TW202413351A (zh) 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法
CN112638381A (zh) 毒蕈碱性乙酰胆碱m1受体拮抗剂
CN117510468A (zh) 双重magl和faah抑制剂
CN115380036A (zh) Sstr5拮抗剂
WO2024149389A1 (zh) 取代桥环类抑制剂及其制备方法和应用
RU2781639C2 (ru) Спироциклические соединения и способы их получения и применения
HK40032869B (en) Spirocycle compounds and methods of making and using same
HK40032869A (en) Spirocycle compounds and methods of making and using same
KR20250117453A (ko) 3-플루오로-4-하이드록시벤즈아미드-함유 억제제 및/또는 분해제 및 이의 용도
EA041386B1 (ru) Спироциклические соединения и способы их получения и применения
HK1256634B (en) Pyrazole compounds and methods of making and using same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20201231

Address after: Tan barley ratio

Applicant after: H. LUNDBECK A/S

Address before: California, USA

Applicant before: Lundbecklahoma Research Center Co.,Ltd.

GR01 Patent grant
GR01 Patent grant